Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC
Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting
You may also be interested in...
Novartis And Daiichi Sankyo Obtain Japanese Price Listings, May Set Precedent For Combination Re-pricing
Japan's Central Social Medical Insurance Agency, also called Chuikyo, recently approved price listings for Novartis' and Daiichi Sankyo's respective potential blockbuster combination diabetes drugs, and the council also agreed to review drug pricing policy to encourage investment in drug innovation
ACC panelist: Study was not powered for outcomes, but doubling in death rates is still "very disturbing."
Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.